SIGN UP
LOG IN
News
Zhaoke Ophthalmology
--
--
0.00%
Weekly Report: what happened at Zhaoke Ophthalmology last week (0512-0516)?
Weekly Report · 2d ago
Weekly Report: what happened at Zhaoke Ophthalmology last week (0505-0509)?
Weekly Report · 05/11 22:06
Weekly Report: what happened at Zhaoke Ophthalmology last week (0428-0502)?
Weekly Report · 05/04 22:06
Zhaoke Ophthalmology Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St · 04/29 22:35
Weekly Report: what happened at Zhaoke Ophthalmology last week (0421-0425)?
Weekly Report · 04/27 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0414-0418)?
Weekly Report · 04/20 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0407-0411)?
Weekly Report · 04/13 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0331-0404)?
Weekly Report · 04/06 22:06
Weekly Report: what happened at Zhaoke Ophthalmology last week (0324-0328)?
Weekly Report · 03/30 22:06
Zhaoke Ophthalmology Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St · 03/25 23:55
ZHAOKE OPHTHALMOLOGY FY REVENUE RMB 69.3 MILLION
Reuters · 03/24 14:37
Weekly Report: what happened at Zhaoke Ophthalmology last week (0317-0321)?
Weekly Report · 03/23 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0310-0314)?
Weekly Report · 03/16 22:06
Weekly Report: what happened at Zhaoke Ophthalmology last week (0303-0307)?
Weekly Report · 03/09 22:06
Weekly Report: what happened at Zhaoke Ophthalmology last week (0224-0228)?
Weekly Report · 03/02 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0217-0221)?
Weekly Report · 02/23 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0210-0214)?
Weekly Report · 02/16 22:06
Retail investors in Zhaoke Ophthalmology Limited (HKG:6622) are its biggest bettors, and their bets paid off as stock gained 22% last week
Simply Wall St · 02/12 23:47
Weekly Report: what happened at Zhaoke Ophthalmology last week (0203-0207)?
Weekly Report · 02/09 22:07
Weekly Report: what happened at Zhaoke Ophthalmology last week (0127-0131)?
Weekly Report · 02/02 22:07
About Zhaoke Ophthalmology
Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company’s products include innovative drugs and generic drugs. The Company ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.